169544-41-6

Basic information

• Product Name: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE
• Synonyms: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE;4-CHLORO-METHYL-DIOXO BENZENEBUTANOIC ACID ETHYL ESTER;4-chloro-β-methyl-α,γ-dioxo-, ethyl ester;ethyl 4-(4-chlorophenyl)-3-Methyl-2,4-dioxobutanoate
• CAS NO: 169544-41-6
• Molecular Formula: C₁₃H₁₃ClO₄
• Molecular Weight: 268.69
• Product Categories: pharmacetical
• Mol File: 169544-41-6.mol

Chemical Properties

• Boiling Point: 397.6 °C at 760 mmHg
• Flash Point: 161.4 °C
• Appearance: /
• Density: 1.241g/cm³
• Vapor Pressure: 1.56E-06mmHg at 25°C
• Refractive Index: 1.522
• CAS DataBase Reference: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE(169544-41-6)
• EPA Substance Registry System: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE(169544-41-6)

Safety Data

• Hazardous Substances Data: 169544-41-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE serves as a valuable precursor for the preparation of a wide range of organic compounds. Its reactivity and functional groups make it suitable for various chemical reactions, enabling the synthesis of complex organic molecules with diverse applications.

InChI:InChI=1/C13H13ClO4/c1-3-18-13(17)12(16)8(2)11(15)9-4-6-10(14)7-5-9/h4-8H,3H2,1-2H3

Upstream product

• 64-17-5 ethanol 
• 6285-05-8 4'-chloropropiophenone 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 1291068-11-5 C₂₀H₁₈ClF₃N₂O₃ 
• 1291068-10-4 C₁₈H₁₈ClN₃O₃ 
• 857855-71-1 [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-yl]methanol 
• 913624-95-0 3-(bromomethyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole 
• 1291068-14-8 5-(4-chlorophenyl)-4-methyl-1-(pyridine-2-yl)-1H-pyrazole-3-carboxylic acid 
• 1291068-12-6 C₁₈H₁₆ClN₃O₂ 
• 1291068-13-7 C₂₀H₁₆ClF₃N₂O₂ 
• 1291068-15-9 5-(4-chlorophenyl)-4-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxylic acid 
• 1291068-16-0 C₁₆H₁₁Cl₂N₃O 
• 1291068-17-1 C₁₈H₁₁Cl₂F₃N₂O 
• 953758-69-5 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(4-methylpiperazin-1-yl)-1H-pyrazole-3-carboxamide 
• 1291067-90-7 O-4332 
• 1291067-91-8 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-[3-(N,N-diethylamino) propyl]-1H-pyrazol-3-carboxamide 
• 1291067-92-9 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(4-methylcyclohexyl)-1H-pyrazol-3-carboxamide 

Relevant articles and documents

MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF

Disclosed are inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.

Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes

The cannabinoid-1 receptor (CB1R) inverse agonist SR141716A has proven useful for study of the endocannabinoid system, including development of divalent CB1R ligands possessing a second functional motif attached via a linker unit. These have predominantly employed the C3 position of the central pyrazole ring for linker attachment. Despite this precedent, a novel series of C3-linked CB1R-D2R divalent ligands exhibited extremely high affinity at the D2R, but only poor affinity for the CB1R. A systematic linker attachment point survey of the SR141716A pharmacophore was therefore undertaken, establishing the C5 position as the optimal site for linker conjugation. This linker attachment survey enabled the identification of a novel divalent ligand as a lead compound to inform ongoing development of high-affinity CB1R molecular probes.

FUSED PYRAZOLE COMPOUNDS AS CB1R ANTAGONISTS AND USES THEREOF

The present invention relates to compounds of formula I, or isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, S-oxides or N- oxides thereof, and processes for their preparation. The invention furt

SUBSTITUTED PYRAZOLE COMPOUNDS AS CB1 RECEPTOR ANTAGONISTS AND USES THEREOF

The present invention relates to compounds of formula 1, or isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, S-oxides or N-oxides thereof, and processes for their preparation. The invention furth

Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake

In spite of rimonabant's withdrawal from the European market due to its adverse effects, interest in the development of drugs based on CB1 antagonists is revamping on the basis of the peculiar properties of this class of compounds. In particular, new strategies have been proposed for the treatment of obesity and/or related risk factors through CB1 antagonists, i.e. by the development of selectively peripherally acting agents or by the identification of neutral CB1 antagonists. New compounds based on the lead CB1 antagonist/inverse agonist rimonabant have been synthesized with focus on obtaining neutral CB1 antagonists. Amongst the new derivatives described in this paper, the mixture of the two enantiomers (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-(2-cyclohexyl-1- hydroxyethyl)-4-methyl-1H-pyrazole ((±)-5), and compound 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[(Z)-2-cyclohexyl-1-fluorovinyl] -4-methyl-1H-pyrazole ((Z)-6), showed interesting pharmacological profiles. According to the preliminary pharmacological evaluation, these novel pyrazole derivatives showed in fact both neutral CB1 antagonism behaviour and significant in vivo activity towards food intake.

'One-pot' synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates via lithium tert-butoxide-mediated sterically hindered Claisen condensation and Knorr reaction

A concise 'one-pot' synthesis of a variety of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates has been developed in moderate to good yields with excellent regioselectivity. Less cost lithium tert-butoxide has been identified as a base for sterically hindered Claisen condensation to efficiently generate the labile 3-substituted 4-aryl-2,4-diketoesters. Furthermore, extensive studies lead to a 'one-pot' process by combination of the Claisen condensation and the Knorr reaction for the synthesis of highly valuable 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates.

Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators

Development of SAR in a 5-aryl-3-acylpyridinyl-pyrazoles and 1-aryl-4-acylpyridinyl imidazoles series of mGlu5 receptor negative allosteric modulators (mGluR5 NAMs) using a functional cell-based assay is described in this Letter. Analysis of the Ligand-lipophilic efficiency (LipE) of compounds provided new insight for the design of potent mGluR5 negative allosteric modulators with anti-depressant activities.

Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold

The CB1 receptor belongs to the G-protein-coupled receptor superfamily. CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. In this study, we report the synthesis and in vitro binding affinity assay of some 1,5-dia

Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral

A safe, functional-group-tolerant and high-throughput version of the trimethylaluminium mediated amide bond formation reaction has been developed in a microreactor system; rimonabant and efaproxiral were prepared to illustrate the utility of the method. The Royal Society of Chemistry.

Synthesis of rimonabant regioisomer

A novel synthesis route for a rimonabant regioisomer was developed.